Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Neovascular Amd: in Cases of Poor Anti-Vegf Response, Switching to Brolucizumab or Faricimab May Help.

Summary by Deutsches Ärzteblatt
Ulm – Not all individuals with neovascular age-related macular degeneration (nAMD) respond to the "classic" anti-VEGF drugs ranibizumab, bevacizumab, and aflibercept to the desired extent. At the University Eye Clinic in Ulm, switching to brolucizumab (BRZ) or faricimab (FAR) has proven successful in such patients...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

Deutsches ÄrzteblattDeutsches Ärzteblatt

Neovascular Amd: in Cases of Poor Anti-Vegf Response, Switching to Brolucizumab or Faricimab May Help.

Ulm – Not all individuals with neovascular age-related macular degeneration (nAMD) respond to the "classic" anti-VEGF drugs ranibizumab, bevacizumab, and aflibercept to the desired extent. At the University Eye Clinic in Ulm, switching to brolucizumab (BRZ) or faricimab (FAR) has proven successful in such patients...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Deutsches Ärzteblatt broke the news in on Tuesday, February 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Ulm, Germany icon

Ulm, Germany

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal